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Literature Review Examining Continuous Subcutaneous Insulin Infusion and Effects on
Hemoglobin A1c, Hypoglycemia, Hyperglycemia/Diabetic Ketoacidosis, and Quality of Life
Chapter 1: Introduction
Diabetes is a life altering disease that can affect children at any age. If diabetes is not
properly controlled, it can lead to severe health problems and even death. An autoimmune
response in the body that targets and destroys the beta cells in the pancreas is responsible for the
development of Type I diabetes in children. Since 1921 researchers have studied the disease
process and to this point there are no answers why this occurs or how to prevent this disease
from happening. The end result of the autoimmune response for children diagnosed with
diabetes is to replace their lack of insulin production either with multiple daily injections (MDI)
with insulin or continuous subcutaneous insulin infusion (CSII) via insulin pump (Buttaro,
Trybulski, Bailey, & Sandberg-Cook, 2008).
Diabetes can be defined as type I or type II diabetes. Type I diabetes requires at least two
insulin injections. Type II diabetes treatment can consist of either oral glucose lowering
medications and/or insulin. It is noted that the incidence of type I diabetes children continues to
rise in the United States. About one in every 400 children and adolescents has type I diabetes.
The percentage of new cases for type I diabetes each year is 19.7 % per 100,000 for individuals
younger than 10 years of age and 18.6 % per 100,000 for individuals older than 10 years of age
according to the National Diabetes Statistics by the National Institutes of Health (2011). The
Center for Disease Control’s (CDC’s) National Diabetes Fact Sheet (2011) found that over 25 %
of people younger than 20, which accounts for 215,000 individuals, are diagnosed annually, with
either type I or type II diabetes. SEARCH for Diabetes in Youth, is a national multi-center
study, which was funded and reported by the CDC and National Institutes of Health (NIH)
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(2011), attempts to understand more about diabetes among children and young adults in the
United States. SEARCH found that each year from 2002 to 2005, over 15,600 individuals
younger than 20 years old, were diagnosed with type I diabetes. The most prevalent ethnic group
affected in children is the non-Hispanic white group with 24.8 % per 100,000 ("National
Diabetes Fact Sheet, 2011," 2011). In 2007, 186,300 school-aged children were diagnosed with
diabetes. Diabetes is considered one of the most common diseases for children in this age group
(Overview of Diabetes in Children and Adolescents from the National Diabetes Education
Program (NDEP), 2011).
Diabetes is also a major financial burden for the United States. The total direct and
indirect cost of taking care of people with diabetes is 174 billion dollars. A diabetic can expect
medical expenditures to be 2.3 times higher than those without diabetes ("National Diabetes Fact
Sheet, 2011," 2011). Diabetes is the leading cause of kidney failure, lower extremity nontraumatic amputations, and new cases of blindness. Diabetes is also a major risk factor for heart
disease and stroke ("National Diabetes Fact Sheet, 2011," 2011). Because of these complications
it is not surprising that diabetes is the seventh leading cause of death in the United States (CDC,
2011). The Diabetes Control and Complication Trial (DCCT) (1993) from 1982 to 1993
examined individuals with Type I diabetes. Data obtained from the trial showed that improved
blood glucose significantly reduces complications caused from poor control. The question that
will be explored in this literature review is: Will children, who are less than 18 years of age,
who are using CSII, for at least one year, have an improved HbA1c, decreased hypoglycemic
episodes, hyperglycemic/diabetic ketoacidosis (DKA) episodes, and improved quality of life
(QOL) over those children who use MDI.
In review of the literature, several definitions were used.

PUMP THERAPY

4

Continuous subcutaneous insulin infusion (CSII), delivers insulin through a
subcutaneous catheter into the individual via an insulin pump, which is controlled by the
individual or care taker. The catheter is changed every two to three days.
Multiple daily injections (MDI) are when the individual gives insulin injections with a
subcutaneous needle. Individuals can be classified as mildly, moderately, or severely
hypoglycemic.
Mild to moderate hypoglycemia is a glucose level less than 70 milligrams per deciliter.
The individual is able to recognize the symptoms of hypoglycemia and take the necessary
treatment steps (Leiter, Yale, Chiasson, Harris, Kleinstiver, and Sauriol, 2005). Severe
hypoglycemia is a glucose reading less than 50 milligrams per deciliter and when the individual
is unable to treat without the assistance from others. Severe hypoglycemia is associated with
seizure and/or loss of consciousness (Weinzimer, 2004).
Diabetic ketoacidosis acidosis (DKA) is caused from hyperglycemia, which leads to
acidosis, dehydration, and osmotic diuresis in the individual. If DKA is severe enough the
individual will need to be hospitalized for rehydration, intravenous infusion of insulin, and
correction of the acid-base imbalance. The range for a fasting blood glucose level is between
110 to 126 milligrams per deciliter (Buttaro et al., 2008).
Hemoglobin A1c (HbA1c) is obtained every three to six months and assists in defining
the level of control of diabetes in the individual. In the literature reviews a normal non-diabetic
HbA1c is 5.6 % or less. A diabetic has a HbA1c of 6.5 % or higher. Higher HbA1c levels
indicate poor control and indicated glucose levels that are above the 126mg/dl ("HbA1c:
MedlinePlus Medical Encyclopedia," 2012).
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Rapid-acting insulin has an average apparent half-life of 81 minutes and lasts about
three to five hours. This insulin is taken five to 10 minutes prior to meals and starts acting in
about 15 minutes. Short-acting insulin should be given 30 to 60 minutes before a meal and the
maximum effect occurs two and half to five hours later. The duration is five to seven hours.
Intermediate-acting insulin begins to lower glucose levels one to four hours after the injection,
and its maximum effect can be seen between fours and 14 hours. Glargine, also known as
Lantus, is a 24 hour basal insulin. This medication is usually given once a day and is used in
combination with a short-acting insulin. There are also no peak action times with this
medication.
Reduction/improvement of HbA1c means that the HbA1C is a lower number than what
it was originally. Significantly lower HbA1c levels indicates improvement in daily glucose levels
which correlates with better diabetic control and reduces the risk of complications that diabetes
causes ("Patient Education," 2010).
The theoretical framework for this capstone project is the Neuman’s System Model. In
this model the basic system/structure is not only the child, but the care givers and medical
professionals as well. The lines of resistance in the model are to protect the child. The older
children can be protected by the care giver and medical professionals. This can be accomplished
by providing necessary education and guidance. The younger children are protected by having
the care givers and medical professionals assist in administration of insulin, strict glucose
control, and meal preparation. Examples of lines of resistance can be education that is provided
about CSII in clinical trial from medical professionals, constant contact with children using CSII,
and support of the care giver. This enables to child to continue using CSII, but can be flexible
based on the needs of the child. The outer two circles of the Neuman’s System Model include
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the normal line of defense and the flexible line of defense. The flexible lines of defense are able
to adjust with the environment. The flexible lines change with the need of the child as in the
case of hyperglycemia. Hyperglycemia can be related to poor eating habits. Encouraging proper
eating habits can aid in improving hyperglycemia. The stability of the basic structure is
dependent on all other factors, whether the factors are internal or external and the ability of the
structure to adapt. This is especially true with diabetic children who have a supportive center
which possess the ability to give and take. This ultimately improves the child’s overall wellbeing (Alligood, 2010).
Chapter 2: Literature Review
Eligibility. Eligibility for articles included in this literature review consisted of several
different criteria. Two main criteria that needed to be present were: the use of CSII in
comparison to MDI and had to include children 18 years old or younger as part of the study.
Other criteria that needed to be present were reported HbA1c levels with CSII use versus MDI
use and hypo-and hyperglycemia episodes with CSII use. Articles that were published before the
year 2000, included adults only, or did not examine pertinent data previously mentioned above
were excluded. Length of study was not a determining factor whether or not to include the
article.
Information Sources. Articles were retrieved from multiple sites. Using the EBSCO
research database accessed via Southern Adventist University website, several articles were
obtained. Other articles were retrieved from the Diabetes Care and American Academy of
Pediatrics on-line archives from previous publications. Ovid Nursing and the National Institute
of Health on-line were also used for article reviews.
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Search. When searching for articles on-line, the search was limited to articles from 2001
to 2012. Criteria that was used to find articles foremost was CSII in children. Other information
used was CSII versus MDI and children, insulin therapy in children, and hypoglycemia in
children.
Study Selection. Articles that were included in the review of literature based on either
the use of CSII or the comparison of CSII with MDI therapy. Hb1Acs were reported comparing
CSII versus MDI use. One article that was included in the review, examined adults and children,
but since the article met the other criteria it was included. If articles did not examine the effects
of CSII on hypoglycemia, hyperglycemia/DKA and/or QOL, the articles were rejected. Some
articles specifically examined the use of CSII in adults. Other articles only reviewed clinical
trials using CSII, which were not included.
Chapter 3: Discussion
The articles that were chosen were reviewed and information was gathered to examine
the PICOT question. Findings concerning HbA1c, hypoglycemia, hyperglycemia/DKA, and
overall effect on the child’s QOL were included in this discussion. All of the findings are
summarized in Appendix A.
HbA1c findings. Nuboer et al. (2008) examined HbA1c in children, ages four to 16,
over a 14 month time frame who used CSII versus MDI therapy. A run-in-phase of three and
one-half months was used at the beginning of the study for all participants. This phase consisted
of the individual using three short-acting insulin injections before meals and one injection of
intermediate-acting insulin at bedtime. After completing the run-in-phase individuals were
separated into either into group A using CSII therapy or group B using MDI therapy. Diabetes
education, constant glucose monitoring, and nutritional advice were given to individuals
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throughout the length of the study. The initial HbA1c for the MDI group was 8.40 ± 1.06% and
at the completion of the study 7.98 ± 0.57%. The CSII group had an initial HbA1c of 8.26 ±
0.80% and at the completion of the study 7.66 ± 0.56%. Although the results did not have a
significant P value, some improvement in lower HbA1c was noted in both groups.
Müller-Godeffroy et al. (2009) studied diabetic children, eight to 16 years of age, from 18
different diabetic treatment centers to compare the effects of switching the participants from
MDI therapy, which was not described in the study, to CSII therapy and if any improvement
would be noted in the QOL and HbA1c. During the transition from MDI to CSII therapy, the
participants were hospitalized from three to seven days for CSII adjustments. The mean HbA1c
in the 12-16 age-group at the start of the study was 8.0 ± 1.56% which was significant with P <
0.05 when compared to the mean HbA1c 7.6 ± 1.33% at the end of the study. The other two age
groups four to seven and eight to 11 did show improvements, but the improvements were not
significant.
Nabhan et al. (2008) compared glycemic control in toddlers and young children, under
the age of five. The participants were initially divided into either the CSII or MDI group. After
six months the MDI group was transitioned to CSII therapy. The mean HBA1c was compared
when compared to HbA1c at the end of the study and there was significant improvement with
HbA1c at the start of the study 8.9 ± 0.6% versus 8.5 ± 0.7% at the end of the study, with P=
0.006. Nabhan also found that the parents whose children used CSII therapy had significantly
lower stress with P < 0.02.
Sulmont et al. (2010) found improvement in HbA1c in children less than six years of age
over eight years. A cohort design was used to assess whether or not the use of CSII would
improve HbA1c and glycemic control long term in children. There were 66 participants, 34 of
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which continued on their current MDI therapy and the other 32 participants were started on CSII
therapy at the time of diagnosis. During the study, the mean reduction in HbA1c in the CSII
group reached statistical significance during year four with P = 0.015, year five with P = 0.010,
and year seven with P = 0.025.
Berhe et al. (2006) evaluated the glycemic control, safety and efficacy of continuous
subcutaneous insulin infusion with pump therapy in two to seven year olds. The participants
were initially on MDI therapy, with at least two injections per day of short-acting insulin and
intermediate-acting insulin, for at least one year prior to the study. At the start of the study the
participants were transitioned to MDI therapy and continued on the same short-acting insulin.
Data was obtained at least one year prior to the study and one year after the study. Berhe found
that before the implementation of the CSII therapy, 65 percent of the children had a HbA1c
greater than 8.5% and after the study, 76 percent of children’s HbA1c was less than 8.5%. Forty
percent of the children in this study had a reduction of greater than 0.8% in HbA1c level, which
was significant with P<.001.
Nelson et al. (2009) examined the HbA1c values during the first 12 months after
changing from MDI to CSII therapy in children nine to 18 years of age. The ideal HbA1c of
7.6% was used as a standard when comparing HbA1c. One month prior to initiation of CSII
therapy the participants’ HbA1c was measured and again at one, four, eight and 12 months. The
participants were divided into five groups. Of the 30 participant’s ages nine to 18 years old,
there were 18 females and 12 males. Group one consisted of five school-age children and three
adolescents and achieved the ideal HbA1c within one month of CSII therapy and able to sustain
the level over 12 months. Group two achieved the ideal HbA1c at the initiation of CSII, but
failed to maintain this at the eight and 12 month HbA1c measurements. Group three was not
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able to meet the ideal HbA1c. Group four’s HbA1c remained above 8% during the 12 months.
The fifth group did not show any constituent trends in either increasing or decreasing HbA1c and
all of the HbA1c’s obtained were above the ideal HbA1c. Nelson felt that the HbA1c was not
achieved by some of the participants because of excessive carbohydrate eating, skipping meals,
or stress in the home causing a decrease in parental involvement.
Weintrob et al. (2003) used a randomized open cross over trial with MDI and CSII
therapy. Participants, ages eight to 14 years of age, were assigned either to the MDI or CSII
group. Participants remained in the groups for three and one-half months and were then
transitioned to the opposite therapy. Three months before the study began, participants, along
with his or her family, were involved in educational sessions. These sessions included strict
glucose monitoring, carbohydrate counting, and insulin adjustments to prevent DKA. The initial
HbA1c three months prior to the study was 8.9 ± 1.0%. At the end of the study the mean HbA1c
was 8.0 ± 0.8%, which is statistically significant with P < .001. However at the end of the study,
the CSII HbA1c was 8.0 ± 0.7% and MDI HbA1c was 8.1 ± 0.8% with P = 0.03. Weintrob
stated that the most likely reason for no difference in HbA1c between the two groups was the
educational sessions prior to the start of the study.
Edwards et al. (2011) examined the use of CSII to see if this would improve glycemic
control in children within one month of the diagnosis of type I diabetes. To be included in this
study, participants, ages eight to 18 years of age, had to have a diagnosis of type I diabetes for
less than four weeks. The participants either continued using MDI therapy or were started on
CSII therapy. HbA1c measurements were taken at the onset of diagnosis, one, three, six, nine,
and 12 months. The CSII group showed lower HbA1c values during the first six month interval
of the study, but did not maintain this at the 12 month interval.
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Doyle et al. (2004) studied whether or not CSII therapy would improve HbA1c in
participants, ages eight to 21 years of age, when compared to MDI therapy using short and longacting insulin, glargine. At the beginning of the study the participants who used MDI therapy
was 8.2 ± 1.1% and the CSII therapy participants HbA1c was 8.1 ± 1.2%. At the end of 16
weeks, those who used CSII therapy had improvement in HbA1c 7.2 ± 1.0% which was
significantly lower compared to the MDI therapy HbA1c 8.1 ± 1.2%. Comparing the mean
baseline HbA1c P < 0.002 and when the HbA1c was compared between the two groups P <
0.005.
Fox et al. (2005) compared an MDI group, using two to three injections per day with
rapid-acting and intermediate-acting insulin, with a CSII group for six months. Participants were
12 to 72 months of age. Despite not having significant improvements in HbA1c between the two
groups, it is noted that CSII group had slight improvement in the HbA1c with baseline HbA1c of
CSII group 7.43 ± 0.48% and at the end of six months HbA1c 7.24 ± 0.31% with P = 0.58 when
compared to the MDI group baseline HbA1c 7.57 ± 0.27% and at the end of six months 7.46 ±
0.18% with P =0.60.
Weinzimer et al. (2004) examined the safety of using CSII in young children under the
age of seven. All of the participants in this study used CSII therapy. At the end of the study,
which was 30 months long, the mean HbA1c for all post-pump visits was 7.1 ± 0.8%. The
children older than three years of age seemed to have modest improvement in HbA1c, although
not significant when compared to the children younger than three. Weinzimer noted that
although there were fewer hypoglycemic episodes and that CSII in young children appears to be
safe, the physician’s evaluation of the child and caregiver should mandate when CSII therapy is
initiated.
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McMahon et al. (2004) examined the impact of CSII in children and adolescents, who
previously had elevated HbA1c, which was not defined in the study, and recurrent hypoglycemic
episodes. HbA1c levels were recorded at the start of CSII therapy and then every three months
for a total of 24 months. Prior to initiating pump therapy the HbA1c was 8.3 ± 0.1% and after
initiation of CSII therapy the HbA1c was 7.8 ± 0.1% with P < 0.001.
Wood et al. (2006) examined from 1998 to 2001 why some youth, from the ages of 11 to
17, chose to continue CSII therapy and why others chose MDI therapy. Wood found that the
ones who chose MDI over CSII therapy were less adherent to monitoring glucose, eating healthy,
and exercising. The youth who continued to use CSII therapy after one year had improvement in
the HbA1c. Wood found that individuals, using CSII therapy, who monitored glucose levels
frequently had a greater improvement in HbA1c. At the end of the study the HbA1c levels using
the CSII therapy was 8.4 ± 1.2 % when compared to those who discontinued CSII therapy and
chose to use MDI therapy the HbA1c was 9.4 ± 2% with P = 0.01.
Burdick et al. (2004) examined the effect of CSII on HbA1c, but more specifically those
children, less than 18 years of age, who already had CSII, greater than six months, and reasons
for less than optimal control. Thirty-five percent of the individuals missed less than one meal
bolus per day had a HbA1c of 8% compared to 65 percent of individuals who missed more than
one meal bolus per day had a significantly increased HbA1c of 8.8% with P = 0.0001. Burdick
pointed out that to continue to have optimal control with CSII, the child or adolescent must
continue to give meal boluses in the same nature he or she would give an injection of insulin, as
in the case of MDI.
Nirmi et al. (2006) examined individuals younger than 40 years of age, who had used
MDI therapy for at least one year prior to using CSII therapy. Participants were divided into

PUMP THERAPY

13

three different groups; the pre-pubertal, adolescent, and young adult. HbA1c levels were
collected when the individuals were using MDI therapy and during the time the individuals were
using CSII therapy. Nimri found that the mean HbA1c levels were lower during the time of CSII
therapy than during the MDI therapy with an average reduction of HbA1c by 0.51% with a P <
.001. The HbA1c during the time of MDI therapy was 8.5 ± 1.5% and the last HbA1c
measurement on CSII therapy was 7.8 ± 1.3%.
Raccah et al. (2009) examined the use of a continuous glucose sensor in diabetic patients
with a HbA1c greater than 8% at the start of the study to see if there was any improvement in
using CSII therapy with the sensor compared to CSII without using the sensor. The study
included adults and children with 51 of the 132 participants being children. Those in the CSII
sensor group had significantly lower HbA1c levels than the CSII non-sensor group with HbA1c
levels.
Plotnick et al. (2003) examined children and adolescents, ages four to 18 years of age, in
a trial for 28 months with CSII and MDI therapy. HbA1c levels were collected for six to 12
months prior to the study and every three months after the study began. During the three to six
months the children and adolescents with CSII therapy had HbA1c levels that were significantly
improved when compared to the start of CSII. When reviewing the HbA1c at the six month
mark there was a notable trend of increasing HbA1c. This rise in HbA1c was thought to be
related to either age or the length of time that the child or adolescent had type I diabetes.
Hypoglycemia. Nuboer et al. (2008) also found a decrease in severe hypoglycemic
events (average of 0.29 episodes), which indicates a threefold reduction of severe hypoglycemic
events that occurred in the CSII group. Sulmont et al. (2010), when comparing CSII to MDI
groups, noted fewer episode of hypoglycemia with P = .016. In the Weinzimer et al. (2008)
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study the rates of hypoglycemic episodes were similar between the two groups. However, it was
noted more hypoglycemic episodes occurred during the day rather than at night which is
consistent with more activity. The risk of hypoglycemia at night related to CSII use continues to
be a concern for many physicians and practitioners, but this study found that hypoglycemia was
more common during the day. Wilson et al. (2005) noted that one CSII participant and one MDI
participant suffered severe hypoglycemic episode, but the CSII participant also had similar
episodes while using MDI prior to the study.
The non-randomized trial by Weinzimer et al. (2004) found significant improvement in
hypoglycemia. In the study, severe hypoglycemia rates decreased as a whole by 53%, from 78
events per 100 patient-years to 37% per 100 patient-years with P = .02. The greatest
improvement noted was in the severe hypoglycemia events occurring in children three to five
years of age, whose rates decreased by 79%, from 141 to 29 events per 100 patient-years P <
.001. Weinzimer pointed out that using CSII in younger children is safe and effective and should
be considered as a treatment plan.
The retrospective study by Nimri et al. (2006) also showed improvement in
hypoglycemia. There were no episodes of severe hypoglycemia in the pre-pubertal group, but in
the adolescent and young adult groups, the number of severe hypoglycemic episodes per 100
patient-years decreased significantly from baseline to one year after initiation of CSII therapy
with P < .01 and P < .05, respectively. Berhe et al. (2006) also noted significant decrease in
hypoglycemia for children who used CSII with a P < .001. Plotnick et al. (2003) examined the
events of hypoglycemia prior to CSII therapy and with CSII therapy. Plotnick found there were
14.3 events per 1,000 patients versus 6.6 per 1,000 patients.
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Hyperglycemia/DKA. Nuboer et al. (2008) also found that with CSII therapy there were
only two episodes of DKA when compared to the MDI group of four episodes. Edwards et al.
(2011) found that amount of time spent in hyperglycemia was decreased 21% in the CSII group
compared to 36% in the MDI group with a P= 0.04. When Weinzimer et al. (2007) compared
aspart insulin versus lispro insulin it was noted that the rate of hyperglycemia was decreased by
11% in the aspart group and 17 % in the lispro group. Even though CSII was not compared to
MDI, the results still indicate a decrease in hyperglycemia episodes. In 2006 Nimri divided
children and adolescents into groups by age and found the DKA of the pre-pubertal age group
with a P = .057 was related to pump technicality. The other two age groups, however, did not
have any DKA episodes. Wilson et al. (2005) found when comparing the hyperglycemia rates
between CSII and MDI therapy, there was no difference noted between the two groups.
Quality of Life. Hilliard et al. (2009) found that youth had more issues with anxiety and
depression prior to starting CSII therapy. At the end of the study the youth had more improved
QOL, improvement in depression and anxiety compared to the youth who used MDI therapy. It
was also found that children, with two or more adults in the home, had a more improved QOL
than children with only one parent which was obtained from the Parent Report Questionnaire.
Müller-Godeffroy et al. (2009) examined if CSII would provide flexibility in lifestyle and
affected family burden. The Overall Diabetes Burden for parents with younger children reported
less of a burden for themselves when the child used CSII. Parents of school-aged children and
adolescents also reported less stress for themselves. Weintrob et al. (2003) found that
participants of the study were more satisfied with CSII therapy rather than MDI therapy. Wilson
et al. (2005) found improvement in the QOL prior to CSII therapy and after completion of the
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study for those participants in the CSII group, but when compared to the MDI group there was
no significant difference.
Fox et al. (2005) examined the burden of disease between the mothers of the CSII and
MDI group. Fox found that the mothers of the MDI group felt more of an impact on life from
the diabetes. Fathers were also examined and it was found that those fathers of the MDI group
felt more psychological distress than those fathers who children used CSII. However, McMahon
et al. (2004) did not see any improvement in the QOL of either the participant or the care giver.
However, participants did report increased self-efficacy scores with CSII therapy.
Limitations. There were several limitations noted throughout this literature review. The
most notable limitation is the small sample sizes that were studied. Partly, this is related to the
fact the studies involved children. Other limitations noted in some of the studies was the length
of time - one study was only 16 weeks long. Not all of the studies examined the same
parameters as described in the PICOT question. There were also fewer articles dealing with CSII
therapy including children over the last two to three years, therefore a majority of the data is
included from 2002 till present. Very few magazines are targeted towards CSII therapy and
therefore many articles came from Diabetes Care. Insurance companies can also be a limitation
in this study because of the cost of CSII therapy, which is very expensive, versus what the
insurance company will pay and provide for the patient. Also, retrieving some articles from online sources required payment for articles being used and because of this, it excluded some
articles from being used.
Chapter 4: Conclusions
By examining all of the articles, specifically targeting Hb1c levels, hypoglycemia,
hyperglycemia/DKA, and QOL certain conclusions can be made. HbA1c, according to the
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majority of the literature reviewed, improves with CSII therapy when compared to MDI therapy.
Yet, it was noted that the CSII therapy improved significantly when the child and/or caregiver
was educated and contacted by medical professionals often. This supports the theory by
Neumann that the system shifts with the environment, but with strengthening of the lines of
defense the core becomes stronger. No specific age group improved more with CSII therapy
with regard to HbA1c than another group. Each study had different age groups that did better
than the other, but at this time it cannot be predicted that the age of the child or adolescent
guarantees better glycemic control over other ages.
When evaluating hypoglycemia and hyperglycemia/DKA, the episodes and the
percentages of these events are decreased with CSII therapy. Only a small percent of the studies
showed no difference between the two groups. This also could be linked with the fact that
education was received about nutrition and checking glucose levels often throughout the day and
night hours. It was noted by several articles that increased amounts of glucose checks decreased
the risk of these events. Some of the studies did show some improvements in the QOL of either
the child or the caregiver. Although several studies commented that a majority of the
participants wanted to continue on CSII therapy after the study was completed rather than MDI
therapy.
It was noted in several of the studies that children and adolescents required less insulin
with CSII therapy when compared to MDI therapy. Also, the BMI decreased with the use of
CSII, which has been postulated by many to actually increase with CSII use. The ultimate goal
of CSII therapy is to provide strict glycemic control while providing flexibility and normalcy to
the child and adolescent. The PICOT question that was asked at the beginning of this literature
review can be supported by the evidence provided in the articles presented. One main
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requirement to be able to meet this improved glycemic control is constant support and education.
Without control, improved glycemic control cannot be achieved.
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Appendix A

HbA1c with M DI use at start and
end of study: 8.40 ± 1.06 compared
to 7.98 ± 0.57.
HbA1c with CSII use at start and end
of study: 8.26 ± 0.80 compared to
7.66 ± 0.56
Nuboer et al.,
2008

Nabhan et al.,
2008

Sulmont et al.,
2010

Examining the changes in the QOL and the
impact of the disease in CSII vs. M DI use
in children

N = 38
Group A = 19
Group B = 19

N = 35
Age = 3.7 ± 0.7
Compare diabetes control, neurocognitive
M ales = 17
functioning, and behavioral/family
Females = 18
functioning in toddlers and young children Duration of diabetes = 1.6 ± 0.6
treated with CSII therapy versus intensive Hemoglobin A1c (HbA1c)= 8.8 ±
insulin injection therapy (IIT).
0.6
Body mass index (BM I) = 79.4 ±
17

Assess the long-term metabolic outcomes
in children who were diagnosed with
diabetes less than six years of age.

N= 66 children
Group A( M DI therapy) = 34
Group B ( CSII therapy) = 16

Randomized,
prospective parallel
design.

No significant improvement in
Pediatric Quality of Life (p < 0.05).
In CSII group, severe hypoglycemic
episodes decreased an average of 0.29
percent indicating a threefold
reduction. M DII = 4 episodes of
DKA compared with CSII with only
two episodes.

M ean HBA1c= 8.9 ± 0.06%.
ANOVA showed significant changes
in HbA1c over time (p= 0.007).

Randomized
Prospective Study
with mixed method
design

Cohort study

No difference between CSII and IIT
(p=0.518) or interaction between
time and group (p=0.454). HbA1c
compared with the baseline mean
decreased significantly over the
yearlong study in both groups (8.9 ±
0.6 versus 8.5 ± 0.7%, p= 0.006).

HbA1c levels in group B (CSII) were
lower than Group A (M DI) during
the eight year follow up. During year
1 HbA1c in group B < 6.5%, P=
.046. The HbA1c compared
between the two groups was
statically significant at 4 years with
P= .015.

Group B had fewer hypoglycemic
episodes than Group A (P = .016).
No difference in DKA between the
two groups.
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Berhe et al., 2006

Evaluate the glycemic control, safety, and
efficacy in CSII in children 2-7 years old
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N= 33

Retrospective Study

HbA1c before (65% of the children
was >8.5%) and after (76% of
children was <8.5%). 40% of the
children had a reduction of >0.8% in
HbA1c level. P<.001.

Hypoglycemia significantly reduced
with a P < .001. Also no reported
seizures with CSII.

Group 1 : 5 school-aged children and
3 adolescents achieved HbA1c of
7.6% within 1 month of CSII therapy
and sustained the level over 12
months. Prior to the study 4 of the 8
had a HbA1c of 7.6% or less.

Examine the HbA1c values during the first
Nelson et al., 2009 12 months of CSII in children 9-18 years
of age.

N= 30
Males= 12
Females=18

A repeated measures
design guided study.

Group 2: 5 school-aged children and
4 adolescents. Three of the
individuals already had HbA1c less
than the target goal. The other 6
individuals actually had a HbA1c
above the target goal.

Group 3: 1 school-aged female and 1
adolescent female. The school-aged
met the HbA1c requirement, but the
adolescent did not.

Group 4: Showed minimal change in
HbA1c but was 8%.

Group 5: No patterns noted in
HbA1c and were all above the target
HbA1c goal.

Weinzimer et
al., 2007

Examine whether it is safe to use lispro or
aspart insulin in CSII in children and
adolescents.

N=298 children and
adolescents
Aspart N= 198
Lispro N= 100

16 week, open label,
multicenter parallelgroup.

The rates of hypoglycemic episodes
were similar between the two groups.
M ore hypoglycemic episodes
occurred during the day rather than at
night which is consistent with more
activity.

In both groups the incidence of
hyperglycemia was lower (aspart
11% and lispro 17%).
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HbA1c was significantly lower from
the start of the study to the first 3
month interval with HbA1c 8.9 ±
1.0% vs. 8.0 ± 0.8%. This change is
thought to be related to increased
glucose monitoring and education
session prior to the study.

Weintrob et al.,
2003

Compare the efficacy and feasibility of
CSII with M DI in children with type 1
diabetes.

Edwards et al.,
2011

Examine if starting CSII at the time of
onset of diabetes preserved C-peptide
secretion and had an improvement in
glycemic control.

N= 23 children (10 males)
Ages 9.4 to 13.9 years with type
1 diabetes.

N=24

A randomized
crossover design

Prospective
randomized pilot
trial

QOL:
The Diabetes Treatment Satisfaction
Questionnaire (DTSQ) and the
Diabetes Quality of Life
Questionnaire for Youth (DQOLY)
were used at the beginning and and at
the end of each treatment arm of the
study. DTSQ satisfaction scale at
beginning of study was 71.9 ± 14.5
and was 74.8 ± 13.5 at the end of the
study. Overall scores of DTSQ at
beginnning of M DI arm, 21.9 ± 3.8
and at the end of the CSII arm 30.6 ±
3.7, (P< .001). No difference noted
in the DQOLY with satisfaction scale
71.9 ± 14.5 at beginnning of study
and 73.5 ± 14.0 at the end of the
study.

HbA1c in the CSII group were lower
are 6 months, but did not maintain
this at the 12 month interval.
Hyperglycemia episodes were
decreased in the CSII group (21% vs.
36%) P= 0.04
HbA1c values were similar between
CSII and current therapy groups at
baseline (7.43 ± 0.48 vs. 7.57 ± 0.27,
CSII vs. current therapy, at 3 months
(7.20 ± 0.29 vs. 7.46 ± 0.22), and at 6
months (7.24 ± 0.31 vs. 7.46 ± 0.18).

Fox et al., 2005

Assess the effects of insulin pump
therapy on diabetes control and family
life in children 1–6 years old with type
1 diabetes.

N = 23
M ales = 13
Females = 10

Randomized control
trial.

QOL:
The pediatric Diabetes Quality of
Life Scale, which was designed for
this study was used examine how the
child's diabetes effected the parent(s)
interaction with the child or the childs
behavior. QOL was examined prior
to the study and again at 6 months.
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Post pump HbA1c: 7.8 (± 0.1)%.
(Range 6.1–10.4%) (P < 0.0001)
Ages < 12 HbA1c pre-pump vs. post
pump: 8.3 ± 0.2% vs. 7.5 ± 0.1% (P
< 0.001).
Ages < 12 H bA1c pre-pump vs.
post pump: 8.4 ± 0.1% vs. 7.9 ±
0.1%.

M cM ahon et al.,
2004

Determine the impact of insulin pump
therapy on key parameters of diabetes
management including quality of life in
children and adolescents with Type 1
diabetes mellitus (T1DM ).

N= 100
M = 41
F = 59
Age < 12 = 40
Age > 12 = 60

Pre pump severe hypoglycemia
(events/100 patient years): for < 12
Design of study not years = 25.9 and > 12 years = 37.5.
Post pump severe hypoglycaemia for
mentioned.
(events/100 patient years): < 12
years = 8.3 and > 12 years = 13.5.

M odified version of the Diabetes
Quality of Life Instrument (DQOL)
was used (not defined in the study).
43 questionnaires were gathered. It
was found the QOL prior to insulin
pump therapy was 63.5 ± 2.1 and
after the study was 68.6 ± 2.1.

M ean HbA1c:
Significantly lower during CSII
therapy than during M DI therapy
(−0.51%; P < .001) for the entire
cohort.
Prepubertal (−0.48%; P < .05);
Adolescent (−0.26%; P < .05); Young
Adult (−0.76%; P < .001) groups

N= 279
Prepubertal= 23 with age range
Compare by age and glycemic control
1.6–8.6 years.
Retrospective paired
continuous subcutaneous insulin infusion
Nimri et al., 2006
Adolescents= 127 with age
study longitudinal
with multiple daily injections in youth
analysis.
ranges 9-17 years.
with type 1 diabetes.
No episodes of severe hypoglycemia
Young adult = 129 with ages
in the prepubertal group. Adolescent
ranges 17-40 years.
and young adult groups, the number

of severe hypoglycemic episodes (per
100 patient-years) decreased
significantly from baseline to 1 year
after initiation of CSII therapy (P <
.01 and P < .05, respectively).

Raccah et al.,
2009

Whether CSII will show improved
metabolic control and evaluate change in
glycemic variability.

N = 132
Children = 51
Adults = 81

Not described

HbA1c were significantly lower
during CSII therapy than during M DI
therapy (−0.51%; P < .001) for the
entire cohort.
Pre-pubertal (−0.48%; P < .05)
Adolescent (−0.26%; P < .05)
Young Adult (−0.76%; P < .001)
groups
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HbA1c was signinicantly improved
after CSII therapy was started (P =
0.03). At 6 months trend noted in
HbA1c to be increasing with (P <
0.001).

Plotnick et al.,
2003

Evaluate safety and effectiveness of CSII
therapy in children and adolescents with
type I diabetes.

N =95
F = 52
M = 43

Not described

Hypoglcemic events decreased after
CSII therapy started. 14.3 per 1,000
patient months prior to CSII and 6.6
per 1,000 patient months after CSII.

One episode of DKA prior to CSII
and one episode during CSII.

Burdick et al.,
2004

Wood et al., 2006

Identify causes of poor glycemic control
in youths who use CSII therapy

Examine reasons for CSII discontinuation
and predictors of insulin pump success.

N = 48
F = 23
M = 25

N = 161

Not described

HbA1c in the 13 to 15 year old age
group had highest HbA1c of 8.8 %
and highest number of missed meal
boluses. Children < 13 had best
HbA1c of 8.4%.

Not described

HbA1c baseline prior to CSII therapy
was 8.4 ± 1.4 a nd a fter 1 yea r of
CSII thera py wa s 8.0 ± 1.3. Thos e
who di s continued CSII thera py
ha d HbA1c a t ba s el i ne pri or to
tryi ng CSII wa s 8.5 ± 1.4 a nd a fter
di s continua tion 8.6 ± 1.3.
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HbA1c range in 4-7 age-groups prior to study
and after: 3.7 to 10.1 compared to 4.7-9.4.
HbA1c range in 8-11 age-groups prior to study
and after: 7.6 ± 0.78% compared to 7.4 ± 0.85%.
HbA1c range in 12-16 age-groups prior to study
and after: 8.0 ± 1.56% compared to 7.6 ± 1.33%.
Significant with P < 0.05.
No significant decrease in severe hypoglycemia.

M üller-Godeffroy et
al., 2009

Investigate different
psychosocial features
which might be relevant
for patients and parents
using CSII therapy

N = 117
M ales - 64
Females - 53
Child age 10.5 ±3.7 years
8-11 years-25
12-16 years- 63
Parents of 4-7 year olds- 29
See table 1 pg. 495

Pilot Study

KINDL_DM : Scores increased significantly in
medium effect size adolescents and large effect
size in school-ages children and younger children.
PIP: Decrease in some of the subscales, but did
not meet previously defined significance level of
P < 0.005.
HFS-P Worry scale: Significant decrease in
hypoglycemia –related worries. Effect size
moderate to large.
HFS-P Behavior Scale: No decrease in this scale
and less frequency of feeding behavior problems.
Effect size moderate to large.
Overall Diabetes Burden: Parents of younger
children reported significantly less burden for
themselves.
M ean t0=3.62 ± 1.06, mean t1 = 3.12 ± 1.1) and
to the child with diabetes (mean t0 = 3.00 ± 1.12,
man t1 = 2.36 ± 0.76.
Difference statistically significant with ( Z = 3.23, -4.15, P< 0.01, Wilcoxon test, two-tailed
testing), with moderate to large effect size (d=
0.5 – 0.8).
Parents of school-age children and adolescents
reported significant less Overall Diabetes Burden
in regard to themselves (8-11 years: mean t0 3.54
±0.92, mean t1= 2.64 ± 0.87, Z= -3.57, P <
0.001; 12-16 years: mean t0 = 2.70 ± 1.01, mean
t1 = 2.40 ± 0.82, Z= -2.36, P < 0.05)
Child with diabetes 8-11 years mean t0= 3.50 ±
0.95, mean t1 = 2.54 ± 1.03, Z= -3.24, P< 0.01
12-16 years: mean t0= 3.07 ± 1.02, mean t1 =
2.64 ± 1.01, Z= -3.05, P <0.01).
Effect size large in school-aged children and
moderate in adolescents.
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Hilliard et al.,
2009

Wilson et al.,
2005

Investigate the changes in quality of life
and of impact of disease by either CSII or
M DII

Prospectively conduct a 1-year,
randomized, controlled, open-label
feasibility trial comparing CSII with M DI
in young children with diabetes.
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N=77
4-7 years old: 9
8-12 years old: 7
13-16 years old: 7
M ales: 17
Females: 21

N= 19 subjects
CSII group = 9
MDI group = 10

Open parallel,
randomized controlled
perspective
comparative study

Significantly decreased HbA1c from
8.34 to 7.82 ( -.052%, p= 0.001).
Within-patient analysis showed a
decreased HbA1c at the end of the 710.5 month CSII period by 0.22%
(p=0.02) while using an average of
0.27U/kg/d less insulin, p< 0.001.
Children with HbA1c levels >8% at
the start of CSII (means 9.1 ± 1.0)
showed a decrease in HbA1c to a
mean of 8.56 ± 1.0 after 7 -10.5
months of CSII 9 p=0.001).

QOL:
The Diabetes Quality of Life for
Youth Scale (DQOL-Y) is a 53 -item
questionnaire that was used to
examine how diabetes impacted the
individuals life, concern about having
diabetes, and satisfaction with life.
The QOL improved most in children,
who had more anxiety, depression,
longer illness duration, and had at
least two adult caregivers in the
home.

Baseline HbA1c: Mean HbA1c
was 8.0% ± 0.8.
HbA1c post study: There was no
significant difference (P = 0.44,
Student’s t test) in the change in
HbA1c between the two groups
(−0.21 ± 0.67%, CSII; 0.04 ± 0.71%,
MDI).
Randomized 1-year
None
of
the
participants
feasibility trial
developed DKA
One CSII and one M DI participants
suffered severe hypoglycemic
episode, but the CSII participant also
had similar episodes while using M DI
prior to study.

Compare the efficacy of CSII to M DI
with glargine in lowering HbA1c levels in
Doyle et al., 2004
children and adolescents with type 1
diabetes.

N=32

Randomized,
prospective trial

HbA1c levels at baseline:
Similar in the glargine and CSII
groups (8.2 ± 1.1 vs. 8.1 ± 1.2%,
respectively, P = 0.89). After 16
weeks of glargine treatment, HbA1c
levels (8.1 ± 1.2%) were not
significantly different from baseline.

HbA1c levels fell sharply in the CSII
group to 7.2 ± 1.0 at 16 weeks (P <
0.02 vs. baseline and P < 0.05 vs.
glargine group).
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QOL:
The pediatric Diabetes Quality of
Life Scale, which was designed for
this study was used examine how the
child's diabetes effected the parent(s)
interaction with the child or the childs
behavior. QOL was examined prior
to the study and again at 6 months.

M ean HbA1c fell from 7.4 ± 1.0% in
the year before pump initiation to 7.0
± 0.9% at 12 months after pump
initiation (P < .001).

Analyze the CSII efficacy and safety data
in very young children with type 1
Weinzimer 2004
diabetes from our Diabetes Clinic
database.

N= 65
Gender, F/M = 38/37
< 3 years= 11
3-< 5 years = 26
5- < 7 years = 28

Non-randomized
uncontrolled design.

Glycemic control improved during
the follow up period; mean HbA1c of
6.8 ± 0.6% at 3 years of follow-up (P
= .003 from prepump values) and 6.5
± 0.9% in the 6 children who amassed
4 years of follow-up. The mean
HbA1c for all postpump visits was
7.1 ± 0.8%, and the mean for each
subject's most recent visit at the time
of data closeout (at a mean duration
of follow-up of 30 months) was 7.0 ±
0.9% (P < .02 from prepump values).

HbA1c levels were most notable in
children < 3 years old, who had a
prepump value of 7.9 ± 1.1% to a
mean postpump value of 6.9 ± 0.9%
(P = .01). “Older” children
experienced a more modest
improvement, from 7.4 ± 0.9% to 7.2
± 0.6% in the 3 to <5 years group,
and from 7.2 ± 0.9 to 7.1 ± 0.9% in
the 5 to < 7 years group, neither of
which reached statistical significance.

SH (severe hypoglycemia) rates
decreased in the group as a whole by
53%, from 78 events per 100 patientyears to 37 per 100 patient-years (P
= .02). The greatest improvement in
SH occurred in the children 3 to < 5
years of age, whose rates decreased
by 79%, from 141 to 29 events per
100 patient-years (P < .001).

DKA: postpump period was 4
episodes per 100 patient-years.

